GlaxoSmithKline Pharmaceuticals has launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for Chronic obstructive pulmonary disease (COPD) patients in a once-daily regime.

The launch follows the product’s approval by the Drugs Controller General of India (DCGI) for use of Trelegy Ellipta as a maintenance treatment to prevent and relieve symptoms associated with COPD in patients aged 18 and above.

In usual clinical care, treatment with single-inhaler Trelegy Ellipta results in significantly more patients with health status improvements and greater lung benefit, versus multi-inhaler triple therapy, with similar safety profiles.

Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers.